Cell Transfection Market Report 2026

The cell transfection market size has grown strongly in recent years. It will grow from $1.42 billion in 2025 to $1.55 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to expansion of molecular biology research, increasing use of gene expression studies, growth in recombinant protein production, rising adoption of in vitro genetic manipulation, availability of diverse transfection methods.

The cell transfection market size is expected to see strong growth in the next few years. It will grow to $2.17 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing development of gene and cell therapies, rising investments in genetic engineering research, growing demand for high-throughput screening assays, expansion of personalized medicine research, increasing use of non-viral delivery technologies. Major trends in the forecast period include increasing adoption of high-efficiency transfection reagents, rising use of viral vector-based transfection, growing demand for scalable transfection methods, expansion of automated transfection platforms, enhanced focus on transfection reproducibility.

The rising incidence of infectious diseases is expected to drive the growth of the cell transfection market in the coming years. Infectious diseases are caused by pathogens that spread from person to person or through contaminated sources. Factors such as inadequate public health infrastructure, vaccine hesitancy, and misinformation have facilitated the spread and evolution of these pathogens. Cell transfection is a critical tool in infectious disease research, allowing scientists to introduce genes into cells to study infection mechanisms and evaluate new treatments. For example, in October 2024, the World Health Organization, a Switzerland-based international public health organization, reported that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from about 7.5 million in 2022, making tuberculosis the leading infectious disease killer. Therefore, the increasing incidence of infectious diseases is propelling the cell transfection market.

Leading companies in the cell transfection market are incorporating technological innovations into transfection systems to achieve precise control over gene expression. A transfection system is a method or technology used to introduce foreign nucleic acids into cells for studying gene function, producing proteins, or altering gene expression. For instance, in July 2024, STEMCELL Technologies, a Canada-based biotechnology company, launched the Cellpore transfection system, designed to advance cell engineering research. This system uses advanced microfluidic technology to deliver various macromolecules into cells efficiently, overcoming limitations of traditional transfection methods. It can transfect up to 10 million cells per second, supporting large-scale applications, and is compatible with multiple cell types, including T cells and hematopoietic stem cells. The system can deliver diverse cargoes, such as small molecules, RNA, proteins, and antibodies.

In July 2023, Sartorius AG, a Germany-based provider of pharmaceutical and laboratory equipment, acquired Polyplus-Transfection SA for $2.6 billion (€2.4 billion). This acquisition positions Sartorius and Polyplus as key players in the rapidly evolving field of cell and gene therapies, combining Sartorius’s expertise with Polyplus’s innovative upstream solutions. Polyplus-Transfection SA, based in France, specializes in providing advanced cell transfection solutions.

Major companies operating in the cell transfection market are Thermo Fisher Scientific Inc., Merck KGaA, Agilent Technologies Inc., Lonza Group AG, Sartorius AG, Sigma-Aldrich Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Stemcell Technologies Inc., GenScript Biotech Corporation, Promega Corporation, Takara Bio Inc., Molecular Devices LLC, New England Biolabs Inc., CureVac SE, OriGene Technologies Inc., Tocris Bioscience, Vector Biolabs, Mirus Bio LLC, Addgene Inc., Altogen Biosystems, Cell Biolabs Inc., Cellecta Inc., ExCell Bio Inc., GeneCopoeia Inc.

North America was the largest region in the cell transfection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell transfection market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell transfection market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the cell transfection market by increasing costs of imported transfection reagents, plasmids, viral vectors, electroporation devices, and laboratory consumables. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on specialized imported reagents, while Asia-Pacific faces higher production costs for export-oriented transfection products. These tariffs are increasing research expenses and slowing experimental timelines. However, they are also encouraging domestic reagent manufacturing, local vector production, and regional innovation in cost-optimized transfection technologies.

The cell transfection market research report is one of a series of new reports that provides cell transfection market statistics, including cell transfection industry global market size, regional shares, competitors with a cell transfection market share, detailed cell transfection market segments, market trends and opportunities, and any further data you may need to thrive in the cell transfection industry. This cell transfection market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cell transfection is a molecular biology technique used to introduce nucleic acids, such as DNA, RNA, or oligonucleotides, into eukaryotic cells. This method enables researchers to study gene function, protein expression, and various cellular processes by modifying the genetic content of the cells. It is an essential tool in genetic engineering, drug discovery, and multiple areas of biomedical research.

The primary cell transfection methods include electroporation, lipofection, calcium phosphate, viral transfection, and others. Electroporation involves applying brief electrical pulses to create temporary pores in cell membranes, allowing genetic material or molecules to enter the cell. These methods are utilized in biomedical research, therapeutic delivery, and protein production, with key end-users including academic and research institutions, pharmaceutical and biotechnology companies, contract research organizations (CROs), and others.

The cell transfection market consists of revenues earned by entities by providing services such as stable cell line development, high-throughput transfection, transient transfection services and viral vector production. The market value includes the value of related goods sold by the service provider or included within the service offering. The cell transfection market also includes sales of reagents, kits, electroporation systems and other related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.